Journal of Thrombosis and Thrombolysis

, Volume 11, Issue 2, pp 175–183 | Cite as

Anaphylactoid Reactions to Vitamin K

  • Louis D. Fiore
  • Michael A. Scola
  • Colleen E. Cantillon
  • Mary T. Brophy
Article

Abstract

Anaphylactoid reactions in patients receiving intravenously administered vitamin K have been reported in the literature. To summarize the known data on anaphylactoid reactions from administration of vitamin K, we reviewed all published and unpublished reports of this adverse reaction. Published reports were obtained through medline (1966–1999) and EMBASE (1971–1999) searches of the English language literature and review of references from identified case reports. Unpublished reports were obtained using the Spontaneous Reporting System Adverse Reaction database of the United States Food and Drug Administration (FDA) between August 1968 and September 1997. All adverse drug reactions to vitamin K were categorized by route of drug administration, dose and standard adverse reaction code. In the FDA reports, we defined anaphylactoid reactions as any adverse drug reaction coded as either anaphylaxis, allergic reaction, apnea, dyspnea, death, heart arrest, hypotension, shock or vasodilatation. Additionally, all fatal and life-threatening FDA reported reactions were reviewed to determine if they could represent an anaphylactoid reaction missed by the above definition.

The literature review uncovered a total of 23 cases (3 fatal) of anaphylactoid reactions from intravenous vitamin K. The FDA database contained a total of 2236 adverse drug reactions reported in 1019 patients receiving vitamin K by all routes of administration. Of the 192 patients with reactions reported for intravenous vitamin K, 132 patients (69%%) had a reaction defined as anaphylactoid, with 24 fatalities (18%%) attributed to the vitamin K reaction. There were 21 patients with anaphylactoid reactions and 4 fatalities reported with doses of intravenous vitamin K of less than 5[emsp4 ]mgs. For the 217 patients with reactions reported due to vitamin K via a non-intravenous route of administration, 38 patients had reactions meeting the definition of anaphylactoid (18%%), with 1 fatality (3%%) attributed to the drug.

The absolute risk of an anaphylactoid reaction to intravenous vitamin K cannot be determined by this study, but the relatively small number of documented cases despite widespread use of this drug suggest that the reaction is rare. Anaphylactic reactions and case fatality reports were found even when intravenous vitamin K was given at low doses by slow dilute infusion. The pathogenesis of this reaction is unknown and may be multifactorial with etiologies including vasodilation induced by the solubilizing vehicle or immune-mediated processes. We conclude that use of intravenous vitamin K should be limited to patients with serious hemorrhage due to a coagulopathy that is secondary to a relative or absolute deficiency of vitamin K.

anaphylaxis vitamin K anticoagulants 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Dam H. The antihaemorrhagic vitamin of the chick. Occurance and chemical nature. Nature 1935;145:652.Google Scholar
  2. 2.
    Fiore L, Deykin D. Anticoagulant therapy. In: Beutler E, et al., eds. Williams Hematology, 5th Edition. McGraw-Hill, Inc., 1995:1562–1584.Google Scholar
  3. 3.
    Vandermeir J. Vitamin K. Thromb Diath Haemorrh 1968;29(Suppl):1–95.Google Scholar
  4. 4.
    Snell AM. Clinical and experimental conditions associated with a deficiency of prothombin. Proc Mayo Clin 1938;13:65.Google Scholar
  5. 5.
    Reynolds DJ, Aronson JK. Anaphylactoid reactions to intravenous vitamin K. Prescribers' J 1992;32(4):167–170.Google Scholar
  6. 6.
    Uses and hazards of vitamin K drugs. Med Lett 1963;5:25(128):97–98.Google Scholar
  7. 7.
    Martin JC. Anaphylactoid reactions and vitamin K. Med J Aust 1991;155:851.Google Scholar
  8. 8.
    Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990;8(7):1263–1268.Google Scholar
  9. 9.
    Weiss RB. Hypersensitivity reactions. Semin Oncol 1992;19(5):458–477.Google Scholar
  10. 10.
    Turner P. Back pain after intravenous vitamin K. Lancet 1959;1:1052.Google Scholar
  11. 11.
    Finkel MJ. Vitamin K1 and the vitamin K analogues. Clin Pharmacol Ther 1961;2(6):794–814.Google Scholar
  12. 12.
    Doctors warned on drug. NY State J Med 1963;Aug15:2430.Google Scholar
  13. 13.
    Udall JA. Don't use the wrong vitamin K. Cal Med 1970;112(4):65–67.Google Scholar
  14. 14.
    Barash P, Kitahata LM, Mandel S. Acute cardiovascular collapse after intravenous phytonadione. Anesth Analg 1976;55(2):304–306.Google Scholar
  15. 15.
    Rich EC, Drage CW. Severe complications of intravenous phytonadione therapy: two cases, with one fatality. Postgrad Med 1982;72(5):303–306.Google Scholar
  16. 16.
    Lefrere JJ, Girot R. Acute cardiovascular collapse during intravenous vitamin K1 injection. Thromb Haemost 1987;58(2):790.Google Scholar
  17. 17.
    Labatut A, Sorbrette F, Virenque CH. Etats de choc lors d'injection de vitamine K. Therapie 1988;43:58.Google Scholar
  18. 18.
    Songy J, Kenneth A, Layon AJ. Vitamin K-induced cardiovascular collapse. J Clin Anesth 1997;9:514–519.Google Scholar
  19. 19.
    de la Rubia J, Grau E, Montserrat I, Zuazu I, Paya A. Anaphylactic shock and vitamin K1. Ann Intern Med 1989;110(11):943.Google Scholar
  20. 20.
    Martinez-Abad M, Delgado F, Palop V, Morales-Olivas F. Vitamin K1 and anaphylactic shock. DICP Ann Pharmacother 1991;25:871–872.Google Scholar
  21. 21.
    Havel M, Muller M, Graininger W, Kurz R, Lindemayr H. Tolerability of a new vitamin K1 preparation for parenteral administration to adults: one case of anaphylactoid reaction. Clin Ther 1987;9(4):373–379.Google Scholar
  22. 22.
    Barnes HM, Sarkany I. Adverse skin reactions from vitamin K1. Br J Dermatol 1976;95:653–656.Google Scholar
  23. 23.
    Bullen AW, Miller JP, Cunliffe WJ, Losowsky MS. Skin reactions caused by vitamin K in patients with liver disease. Br J Dermatol 1978;98:561–565.Google Scholar
  24. 24.
    Robison MJ, Odom CRB. Delayed cutaneous reaction to phytonadione. Arch Dermatol 1978;114:1790–1792.Google Scholar
  25. 25.
    Finkelstein H, Champion MC, Adam JE. Cutaneous hypersensitivity to vitamin K1 injection. J Am Acad Dermatol 1987;16:540–545.Google Scholar
  26. 26.
    Heydenreich G. A further case of adverse skin reaction from vitamin K1. Br J Dermatol 1977;97:697.Google Scholar
  27. 27.
    Whiting AM, Bussey H, Lyons R. Comparing different routes and doses of phytonadione for reversing excessive anticoagulation. Arch Intern Med 1998;158:2136–2140.Google Scholar
  28. 28.
    Raj G, Kumar R, McKinney WP. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. Arch Intern Med 1999;159:2721–2724.Google Scholar
  29. 29.
    Hirsh J, Dalen JE, Anderson D, et al. Oral Anticoagulants: Mechanisms of action, clinical effectiveness, and optimal therapeutic range. Chest 1998;114:445S–469S.Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • Louis D. Fiore
    • 1
  • Michael A. Scola
    • 1
  • Colleen E. Cantillon
    • 1
  • Mary T. Brophy
    • 1
  1. 1.Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, 150 South Huntington AvenueBoston

Personalised recommendations